Background And Purpose: Diffuse lower-grade gliomas are classified into prognostically meaningful molecular subtypes. We aimed to determine the impact of surgical resection on overall survival in lower-grade glioma molecular subtypes.
Materials And Methods: For 172 patients with lower-grade gliomas (World Health Organization grade II or III), pre- and postsurgical glioma volumes were determined using a semiautomated segmentation software based on FLAIR or T2-weighted MR imaging sequences. The association of pre- and postsurgical glioma volume and the percentage of glioma resection with overall survival was determined for the entire cohort and separately for lower-grade glioma molecular subtypes based on () and 1p/19q status, after adjustment for age, sex, World Health Organization grade, chemotherapy administration, and radiation therapy administration.
Results: For the entire cohort, postsurgical glioma volume (hazard ratio, 1.80; 95% CI, 1.18-2.75; = .006) and the percentage of resection (hazard ratio, 3.22; 95% CI, 1.79-5.82; < .001) were associated with overall survival. For -mutant 1p/19q-codeleted oligodendrogliomas, the percentage of resection (hazard ratio, 6.69; 95% CI, 1.57-28.46; = .01) was associated with overall survival. For -mutant 1p/19q-noncodeleted astrocytomas, presurgical glioma volume (hazard ratio, 3.20; 95% CI, 1.22-8.39; = .018), postsurgical glioma volume (hazard ratio, 2.33; 95% CI, 1.32-4.12; = .004), and percentage of resection (hazard ratio, 4.34; 95% CI, 1.74-10.81; = .002) were associated with overall survival. For -wild-type lower-grade gliomas, pre-/postsurgical glioma volume and percentage of resection were not associated with overall survival.
Conclusions: The extent of surgical resection has a differential survival impact in patients with lower-grade gliomas based on their molecular subtype. -mutant lower-grade gliomas benefit from a greater extent of surgical resection, with the strongest impact observed for -mutant 1p/19q-noncodeleted astrocytomas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048539 | PMC |
| http://dx.doi.org/10.3174/ajnr.A6102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of PDGFB.
Immunotargets Ther
January 2025
Institute of Integration of Traditional Chinese and Western Medicine, The Hospital Affiliated to Jiangnan University, Wuxi, People's Republic of China.
Introduction: Cancer is a widespread epidemic that affects millions of individuals across the world. Identifying novel cancer targets is crucial to developing more effective cancer treatments. Platelet-derived growth factor-B (PDGFB) plays a critical role in various tumor processes, including angiogenesis and lymphatic metastasis.
View Article and Find Full Text PDFIDH1 mutation inhibits differentiation of astrocytes and glioma cells with low oxoglutarate dehydrogenase expression by disturbing α-ketoglutarate-related metabolism and epigenetic modification.
Life Metab
April 2024
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Isocitrate dehydrogenase (IDH) mutations frequently occur in lower-grade gliomas and secondary glioblastomas. Mutant IDHs exhibit a gain-of-function activity, leading to the production of D-2-hydroxyglutarate (D-2HG) by reducing α-ketoglutarate (α-KG), a central player in metabolism and epigenetic modifications. However, the role of α-KG homeostasis in IDH-mutated gliomagenesis remains elusive.
View Article and Find Full Text PDFIntegration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma.
Front Pharmacol
January 2025
Department of Neurological Function Examination, Affiliated Hospital of Hebei University, Baoding, China.
Background: Lower-grade glioma (LGG) exhibits significant heterogeneity in clinical outcomes, and current prognostic markers have limited predictive value. Despite the growing recognition of histone modifications in tumor progression, their role in LGG remains poorly understood. This study aimed to develop a histone modification-based risk signature and investigate its relationship with drug sensitivity to guide personalized treatment strategies.
View Article and Find Full Text PDFAssessing the Validity of Diffusion Weighted Imaging Models: A Study in Patients with Post-Surgical Lower-Grade Glioma.
J Clin Med
January 2025
Department of Radiology, Medical Imaging Center, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Diffusion weighted imaging (DWI) is used for monitoring purposes for lower-grade glioma (LGG). While the apparent diffusion coefficient (ADC) is clinically used, various DWI models have been developed to better understand the micro-environment. However, the validity of these models and how they relate to each other is currently unknown.
View Article and Find Full Text PDFBrain mapping for lower-grade glioma around Wernicke's area.
Neurosurg Focus Video
January 2025
Department of Neurosurgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; and.
Surgery of lesions around Wernicke's area is challenging for several reasons. The anatomical boundaries are not clearly defined, necessitating functional identification in addition to anatomical landmarks. There are potential complications secondary to injury of the surrounding structures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!